HBM Holdings-B (02142) saw its stock price soar 6.59% during the intraday trading session, reaching HK$14.68. The surge comes on the heels of a significant announcement made by the company regarding its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd.

On November 19, HBM Holdings-B revealed that Nona Biotechnology had entered into a non-exclusive license agreement with pharmaceutical giant Pfizer. This partnership aims to advance preclinical antibody discovery for multiple potential disease indications. Under the terms of the agreement, Pfizer will gain global access to Nona Biotechnology's proprietary HCAb platform, which is used for developing fully human heavy-chain-only antibodies.

The deal structure includes an upfront payment to Nona Biotechnology, with the potential for additional regulatory, clinical, and commercial milestone payments. Furthermore, the agreement opens up opportunities for collaborative efforts between Nona Biotechnology and Pfizer, leveraging the former's HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering. This strategic partnership has evidently boosted investor confidence, contributing to the significant uptick in HBM Holdings-B's stock price.